Abstract
Approximately 5.7 million people died from stroke in 2005 [1]. According to World Health Organization estimates, figures are predicted to increase to 23 million first-ever strokes, 77 million stroke survivors, 61 million disability adjusted life years (DALYs) and 7.8 million deaths in the next 20 years [2]. Heart disease and stroke are leading causes of DALYs lost and deaths worldwide [3]. Over 70 % of ischemic strokes are first events, which makes primary prevention immensely important. The treatments for acute ischemic stroke have emerged during the last decade and there is growing evidence of efficacy and importance of secondary prevention. We foresee that patients at high risk of vascular events could reduce their risk by 75 to 80 % through optimal prevention strategies including a combination of lifestyle changes and medical therapy [4]. In this review, we will focus on the aspects of antithrombotic treatment of ischemic stroke (IS) in the primary and secondary prevention.
Keywords: Stroke, cerebral infarction, antiplatelet medication, antithrombotics, anticoagulants, aspirin, warfarin, prevention
Current Drug Targets
Title: Antithrombotic Treatment in the Prevention of Ischemic Stroke
Volume: 8 Issue: 7
Author(s): Ufuk Emre, Kirsi Rantanen and Turgut Tatlisumak
Affiliation:
Keywords: Stroke, cerebral infarction, antiplatelet medication, antithrombotics, anticoagulants, aspirin, warfarin, prevention
Abstract: Approximately 5.7 million people died from stroke in 2005 [1]. According to World Health Organization estimates, figures are predicted to increase to 23 million first-ever strokes, 77 million stroke survivors, 61 million disability adjusted life years (DALYs) and 7.8 million deaths in the next 20 years [2]. Heart disease and stroke are leading causes of DALYs lost and deaths worldwide [3]. Over 70 % of ischemic strokes are first events, which makes primary prevention immensely important. The treatments for acute ischemic stroke have emerged during the last decade and there is growing evidence of efficacy and importance of secondary prevention. We foresee that patients at high risk of vascular events could reduce their risk by 75 to 80 % through optimal prevention strategies including a combination of lifestyle changes and medical therapy [4]. In this review, we will focus on the aspects of antithrombotic treatment of ischemic stroke (IS) in the primary and secondary prevention.
Export Options
About this article
Cite this article as:
Ufuk Emre , Kirsi Rantanen and Turgut Tatlisumak , Antithrombotic Treatment in the Prevention of Ischemic Stroke, Current Drug Targets 2007; 8 (7) . https://dx.doi.org/10.2174/138945007781077409
DOI https://dx.doi.org/10.2174/138945007781077409 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Approaches for Reducing C-Reactive Protein (CRP) Levels and the Associated Cardiovascular Risk
Current Chemical Biology Multi-Constituent Cardiovascular Pills (MCCP) - Challenges and Promises of Population-Based Prophylactic Drug Therapy for Prevention of Heart Attack
Current Pharmaceutical Design Aspartic Proteinases in Disease: A Structural Perspective
Current Drug Targets Effects of ACE Inhibitors on Skeletal Muscle
Current Pharmaceutical Design Should Adipokines be Considered in the Choice of the Treatment of Obesity-Related Health Problems?
Current Drug Targets Spontaneous Coronary Artery Dissection: Does Being Unemployed Matter? Insights from the GSCAD Registry
Current Cardiology Reviews Synthetic Cannabinoids as Drugs of Abuse
Current Drug Abuse Reviews Soy Isoflavones and Exercise: Possible Benefits for Postmenopausal Womens Cardiovascular Health
Current Women`s Health Reviews Obesity-Associated Hypertension in Childhood: A New Epidemic Problem
Current Hypertension Reviews Recent Advances Using Phosphodiesterase 4 (PDE4) Inhibitors to Treat Inflammatory Disorders: Animal and Clinical Studies
Current Drug Therapy Assessing Myocardial Metabolism with Hybrid PET Imaging: Instrumentation, Concepts, and Workflows
Current Pharmaceutical Design Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Recent Valves used for Transluminal Implantation in Patients with Aortic Valve Stenosis
Recent Patents on Cardiovascular Drug Discovery p66 Shc as the Engine of Vascular Aging
Current Vascular Pharmacology Triglycerides and Cardiovascular Risk
Current Cardiology Reviews A Study of Prescription Pattern and Compliance of Anti-hypertensives with the Treatment Guidelines in Aseer Region; Saudi Arabia
Current Drug Therapy Therapeutic Neovascularization by the Implantation of Autologous Mononuclear Cells in Patients with Connective Tissue Diseases
Current Pharmaceutical Design Cellular Cardiomyoplasty and Cardiac Regeneration
Current Cardiology Reviews The Roles of Cytochrome P450 in Ischemic Heart Disease
Current Drug Metabolism Emerging Role for Antioxidant Therapy in Protection Against Diabetic Cardiac Complications: Experimental and Clinical Evidence for Utilization of Classic and New Antioxidants
Current Cardiology Reviews